PFM Health Sciences LP Invests $3.06 Million in Pulmonx Co. (NASDAQ:LUNG)

PFM Health Sciences LP purchased a new stake in Pulmonx Co. (NASDAQ:LUNG) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 368,929 shares of the company’s stock, valued at approximately $3,058,000. PFM Health Sciences LP owned about 0.93% of Pulmonx as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Squarepoint Ops LLC boosted its stake in shares of Pulmonx by 261.2% in the second quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock worth $916,000 after buying an additional 104,432 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Pulmonx in the 3rd quarter worth approximately $102,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Pulmonx by 7.0% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock worth $6,714,000 after purchasing an additional 69,595 shares during the period. XTX Topco Ltd purchased a new position in shares of Pulmonx during the 2nd quarter valued at approximately $222,000. Finally, Millrace Asset Group Inc. acquired a new position in shares of Pulmonx in the 3rd quarter valued at $1,390,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Insider Buying and Selling at Pulmonx

In related news, General Counsel David Aaron Lehman sold 5,765 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $6.69, for a total value of $38,567.85. Following the completion of the sale, the general counsel now owns 203,348 shares of the company’s stock, valued at approximately $1,360,398.12. This trade represents a 2.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $6.52, for a total value of $130,400.00. Following the transaction, the director now owns 1,091,974 shares in the company, valued at approximately $7,119,670.48. The trade was a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 70,351 shares of company stock valued at $494,094 over the last quarter. 5.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Separately, Stifel Nicolaus dropped their price target on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.67.

Pulmonx Price Performance

Shares of NASDAQ LUNG opened at $6.45 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The firm has a market cap of $254.71 million, a PE ratio of -4.39 and a beta of 0.68. Pulmonx Co. has a one year low of $5.46 and a one year high of $14.84. The firm has a fifty day moving average of $6.87 and a 200 day moving average of $7.05.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. The firm had revenue of $20.39 million during the quarter, compared to the consensus estimate of $20.39 million. During the same quarter in the prior year, the firm earned ($0.39) EPS. As a group, research analysts predict that Pulmonx Co. will post -1.53 EPS for the current fiscal year.

Pulmonx Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.